Rallybio Corporation — Balance Sheet (NASDAQ:RLYB) | MetaTrader

Open full chart

Financials

Overview 明細書 Statistics Dividends

Quarterly Annual

Total assets 182.19 M180.44 M115.62 M68.11 M Total liabilities 6.58 M11.12 M9.44 M6.45 M Total equity 175.6 M169.32 M106.18 M61.65 M Total liabilities & shareholders' equities 182.19 M180.44 M115.62 M68.11 M Total debt ———— Net debt ————

ニュース

Rallybio CFO Lieber氏、3992ドル相当の株式を売却

Lieber, Rallybio CFO, sells $3992 in shares

Rallybio reports positive phase 1 results for subcutaneous C5 inhibitor

Rallybio announces one-for-eight reverse stock split effective Feb 6

Upcoming Stock Splits This Week (February 2 to February 6) – Stay Invested - TipRanks.com

Rallybioが2026年2月6日付で1対8の株式併合を実施

Rallybio to implement 1-for-8 reverse stock split effective February 6

Rallybio completes first cohort dosing in RLYB116 C5 inhibitor study

Here's Why Shares in Recursion Pharmaceuticals Surged Today

Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio

Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Rallybio (NASDAQ:RLYB), Recursion Pharmaceuticals (NASDAQ:RXRX)

Rallybio sells HPP treatment program to Recursion for up to $25 million